Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ARCT | Arcturus Therapeutics | $10.08 | -$13.08 | -0.56% | 152.2K | $628.9M | $8.04$24.17 |
| ATOM | Atomera | $2.66 | -$1.59 | -0.37% | 741.7K | $133.8M | $2.48$17.55 |
| ATMV | AlphaVest Acquisition Corp | $10.32 | -$3.18 | -0.24% | 61.8K | $52.0M | $8$42 |
| OWLS | Obook | $18.16 | -$1.35 | -0.07% | 15.5K | $1.7B | $10$90 |
| NERV | Minerva Neurosciences | $5.54 | -$0.87 | -0.14% | 918.4K | $44.8M | $1.15$12.46 |
| OKLL | Tidal Trust II - Defiance Daily Target 2x Long Oklo ETF | $81.86 | -$4.48 | -0.05% | 334.9K | - | $16.09$169.96 |
| GNPX | Genprex | $10.08 | -$1.42 | -0.12% | 37.1K | $493.4M | $7$157.5 |
| RYOJ | rYojbaba | $6.84 | -$2.28 | -0.25% | 180.9K | $102.6M | $1.81$11.43 |
| VELO | Velo3D, Inc. | $5.92 | -$1.08 | -15.43% | - | - | - |
| GLGG | Themes ETF Trust - Leverage Shares 2x Long Glxy Daily ETF | $35.85 | -$4.93 | -0.12% | 8.6K | - | $12.38$45.8 |
Related Articles
Featured Article
Could Arcturus Therapeutics Be the Next Moderna?
Alex Carchidi|Mar 1, 2022
It's not likely, but it could still end up being a good investment.
Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
Adria Cimino|Oct 15, 2021
The company disappointed last year, but things may be turning around.
September Sell-Off: Buy These Stocks While They're Down
Anders Bylund|Sep 22, 2021
Successful investors buy great stocks when everyone else is selling in a panic. These high-quality stocks are trading at a market-risk discount right now and you should take advantage of these generous buying windows.
Could Newegg Stock Blast Off Once Again?
Zhiyuan Sun|Jul 22, 2021
Meme stock tailwinds could only lift the popular computer hardware retailer so far for so long.
Does Newegg's Stock Price Match Its Prospects?
Zhiyuan Sun|Jul 16, 2021
This computer parts supplier has more going for it than meets the eye, but is it overvalued?
These 2 Big Nasdaq Winners Are Defying the Downturn Wednesday
Dan Caplinger|Jul 7, 2021
Pressure on major indexes isn't hurting all stocks.
Which Late-to-the-Party COVID Vaccine Stocks Could Still Be Winners?
Keith Speights and Brian Orelli, PhD|Mar 14, 2021
There's at least one biotech that appears to be a potential contender.
Is Arcturus Therapeutics a Buy?
Alex Carchidi|Jan 12, 2021
Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.
Did You Miss Out on the Chance for Big Gains from Arcturus Stock?
Adria Cimino|Jan 6, 2021
The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.
Why Is Everyone Talking About Arcturus Therapeutics Stock?
Zhiyuan Sun|Jan 5, 2021
This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.
